Keryx Biopharm Inc (KERX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2017 | 03-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -109,513 | -23,016 | -161,095 | -127,311 | -85,615 |
| Depreciation Amortization | 63,302 | 167 | 34,988 | 34,819 | 34,624 |
| Income taxes - deferred | 39 | 20 | 80 | 60 | 40 |
| Accounts receivable | -3,223 | -917 | -1,580 | 3,656 | -1,445 |
| Other Working Capital | -5,431 | -7,023 | -7,943 | -6,144 | -6,584 |
| Other Operating Activity | 10,669 | 4,806 | 48,946 | 28,668 | 16,382 |
| Operating Cash Flow | $-44,157 | $-25,963 | $-86,604 | $-66,252 | $-42,598 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -420 | N/A | -2,074 | -2,064 | -2,040 |
| Investing Cash Flow | $-420 | $N/A | $-2,074 | $-2,064 | $-2,040 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 73,382 | 5,090 | 198 | 198 | 144 |
| Other Financing Activity | -88 | -28 | 0 | 0 | 0 |
| Financing Cash Flow | $73,294 | $5,062 | $198 | $198 | $144 |
| Beginning Cash Position | 111,810 | 111,810 | 200,290 | 200,290 | 200,290 |
| End Cash Position | 140,527 | 90,909 | 111,810 | 132,172 | 155,796 |
| Net Cash Flow | $28,717 | $-20,901 | $-88,480 | $-68,118 | $-44,494 |
| Free Cash Flow | |||||
| Operating Cash Flow | -44,157 | -25,963 | -86,604 | -66,252 | -42,598 |
| Capital Expenditure | -420 | N/A | -2,074 | -2,064 | -2,040 |
| Free Cash Flow | -44,577 | -25,963 | -88,678 | -68,316 | -44,638 |